Business
Clinical Trials CHK1 Inhibitor CCT245737 to Open
Clinical Trials CHK1 Inhibitor CCT245737 to Open.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0045Z Sareum Holdings PLC 23 May 2016 \n\n\n\n\n\n(AIM: SAR)\n\n\n23 May 2016\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nClinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital\nSareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that the Phase I clinical trials of CHK1 inhibitor drug candidate CCT245737 are anticipated to open at the Royal Marsden Hospital, Sutton on 31 May 2016.\nTwo Phase I clinical trials in cancer patients are being conducted, in collaboration with co-development partners, the CRT Pioneer Fund. One trial will use CCT245737 in combination with standard-of-care chemotherapy and will ultimately target lung and pancreatic cancer patients. The other trial will use CCT245737 as a single anti-cancer agent and will initially target various cancers.\nAs noted in its announcements of 1 February 2016 and 5 April 2016, Sareum satisfied a financial commitment of £797,500 to the funding of these trials in December 2015. The submission of the Clinical Trial Applications in February 2016 triggered the receipt by Sareum of a £200,000 success milestone payment.\nFurther details of these clinical trials will be posted on the UK Clinical Trials Gateway at https://www.ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialId=35145 (chemotherapy combination) and https://www.ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialId=35146 (single agent) in due course.\nSareum's CEO, Dr Tim Mitchell, commented: \"We are very pleased to report the anticipated start of the two clinical trials of CCT245737, the first from our development pipeline to be dosed in cancer patients.\"\nFor further information:\n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / Nick Prowting\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce / William Lynne\n\n\n020 3764 2341/2342\n\n\n\n\nThe Communications Portfolio (Media enquiries)\n\n\n \n\n\n\n\nAriane Comstive\[email protected] \n\n\n07785 922 354\n\n\n\n\nNotes for editors:\nSareum is a drug discovery and development company delivering targeted small molecule therapeutics,...